US Patent

US10112903 — Heterocyclic compounds for the treatment of neurological and psychological disorders

Method of Use · Assigned to Alkermes Pharma Ireland Ltd · Expires 2030-06-24 · 4y remaining

Vulnerability score 51/100 Moderate — design-around opportunities exist

What this patent protects

This patent discloses lactam compounds for the treatment of neurological and psychiatric disorders, including schizophrenia and bipolar disorder.

USPTO Abstract

Lactam compounds of Formula I and their use for the treatment of neurological and psychiatric disorders including schizophrenia, bipolar disorder, anxiety disorder and insomnia is disclosed.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-543 — Aristada
U-543 — Aristada
U-543 — Aristada
U-543 — Aristada
U-543 — Aristada

Patent Metadata

Patent number
US10112903
Jurisdiction
US
Classification
Method of Use
Expires
2030-06-24
Drug substance claim
Yes
Drug product claim
No
Assignee
Alkermes Pharma Ireland Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.